Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | RBP4 | P02753 | 3/20 | 0.43 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.42 |
| ▸ | GLRB | P48167 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251405 | 0.86 | CES2 (0.44) | KEAP1CES2CES1RBP4KMT2A | |
| SCHEMBL13145643 | 0.86 | KEAP1 (0.53) | KEAP1CES2CES1RBP4GLRA3 | |
| SCHEMBL8976949 | 0.85 | CES2 (0.42) | KEAP1CES2CES1RBP4KMT2A | |
| SCHEMBL334641 | 0.82 | KEAP1 (0.52) | KEAP1CES2CES1RXRBKMT2A | |
| SCHEMBL8572602 | 0.80 | KEAP1 (0.50) | KEAP1CES2CES1NOTUMKMT2A | |
| SCHEMBL195743 | 0.78 | TDP1 (0.44) | GLRA3GLRBTDP1RXRBATM | |
| SCHEMBL1355541 | 0.78 | TDP1 (0.54) | GLRA3GLRBTDP1RXRBKDM4E | |
| SCHEMBL29654078 | 0.78 | ALDH1A1 (0.57) | CES2GLRA3GLRBTDP1RXRB | |
| SCHEMBL4631399 | 0.78 | TDP1 (0.59) | GLRA3GLRBTDP1NOTUMRXRB | |
| SCHEMBL38809 | 0.78 | ALDH1A1 (0.57) | CES2GLRA3GLRBTDP1RXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355113-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-11-18 | — | — | US | disclosed |
| EP-2291358-B1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8623818-B2 | Glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2000048993-A1 | ARYLAMINOALKYLAMIDES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-0640080-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS. | SYNTEX INC (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5380739-A | Angiotensin II antagonists | SYNTEX (U.S.A.) INC. (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1993023391-A1 | SUBSTITUTED INDOLES AND AZAINDOLES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | KEAP1 3258/4885CES2 2026/4885CES1 486/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | KEAP1 2827/4885CES2 2065/4885CES1 436/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | KEAP1 3258/4885CES2 2026/4885CES1 486/4885 |
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KEAP1 485/4885CES2 2983/4885CES1 1856/4885 |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | KEAP1 710/4885CES2 3243/4885CES1 296/4885 |
| US-20210355113-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | KEAP1 850/4885CES2 1371/4885CES1 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.